Apratastat

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameApratastat
Drug Alias Name阿他司他Apratastatum阿雷司他TMI-005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 17 inhibitorsMatrix metalloproteinase inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 17Matrix metalloproteinase
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth Llc
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksKEGG